Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
University Medical Center Hamburg-Eppendorf
Hamburgo, AlemaniaPublicaciones en colaboración con investigadores/as de University Medical Center Hamburg-Eppendorf (84)
2024
-
APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer’s cases
Frontiers in Molecular Neuroscience, Vol. 17
-
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Haematologica
-
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387
-
Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile
Neuro-oncology, Vol. 26, Núm. 9, pp. 1723-1737
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
-
Recent outcomes of liver transplantation for Budd-Chiari syndrome: A study of the European Liver Transplant Registry (ELTR) and affiliated centers
Hepatology, Vol. 80, Núm. 1, pp. 136-151
-
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
New England Journal of Medicine, Vol. 391, Núm. 1, pp. 44-55
2023
-
Advancing with cancer immunotherapeutics: CD29+ regulatory T cell antagonism
Gut
-
An indirect treatment comparison of efficacy and health-related quality of life following treatment with idecabtagene vicleucel versus belantamab mafodotin in triple-class exposed relapsed/refractory patients with multiple myeloma
Leukemia and Lymphoma
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma: Final Data from the Phase 2 ELOQUENT-3 Trial
HemaSphere, Vol. 7, Núm. 3, pp. E843
-
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311
-
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
The Lancet Oncology, Vol. 24, Núm. 6, pp. e255-e269
-
Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline
Annals of Oncology, Vol. 34, Núm. 5, pp. 452-467
2022
-
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial
Gynecologic Oncology, Vol. 164, Núm. 2, pp. 254-264
-
Erratum to ‘Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors’: [ESMO Open Volume 7, Issue 2, April 2022, 100447] (ESMO Open (2022) 7(2), (S2059702922000631), (10.1016/j.esmoop.2022.100447))
ESMO Open
-
Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts
JAMA Oncology, Vol. 8, Núm. 3
-
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
Leukemia, Vol. 36, Núm. 5, pp. 1371-1376
-
Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
ESMO Open, Vol. 7, Núm. 2